Novacyt

Equities

ALNOV

FR0010397232

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:03 2024-07-17 EDT			5-day change	1st Jan Change
0.525 ^EUR	-7.08%		-9.01%	-26.37%

06-11	Novacyt, UK Department of Health and Social Care Settle Dispute	MT
06-11	Novacyt settles with UK government over Covid-19 test kit claims	AN

Novacyt Announces Unaudited Consolidated Revenues Results for the Full Year Ended December 31, 2015

January 13, 2016 at 09:20 am

Novacyt announced unaudited consolidated revenues results for the full year ended December 31, 2015. The consolidated group sales for 2015 were €8.9 million compared with €4.5 million in 2014, representing 98% growth. On a pro forma basis sales of the group for 2015 were €8.9 million compared to €7.8 million in 2014, representing 14% growth.

Latest news about Novacyt

Novacyt, UK Department of Health and Social Care Settle Dispute	06-11	MT
Novacyt settles with UK government over Covid-19 test kit claims	06-11	AN
Novacyt: litigation settlement weighs on share price	06-11	CF
Novacyt S.A. Announces Settlement of Dispute with Department of Health and Social Care	06-11	CI
EARNINGS AND TRADING: TPXimpact expects growth; Novacyt loss widens	05-30	AN
Novacyt: losses widen in 2023, share price falls	05-30	CF
Transcript : Novacyt S.A., 2023 Earnings Call, May 30, 2024	05-30
Novacyt Says UK Court Dismissed Government's Summary Judgment Application	05-01	MT
Novacyt notes court dismissal of UK DHSC summary judgment application	05-01	AN
Novacyt: confident ahead of DHSC trial	04-19	CF
Novacyt expects court to dismiss application by UK DHSC	04-19	AN
Novacyt expects court to dismiss application by UK DHSC	04-19	AN
AIM WINNERS & LOSERS: Ethernity loss narrows; Fonix staff sell shares	04-19	AN
Yourgene CEO to become head of Novacyt after acquisition	04-11	AN
Novacyt: changes to the Board of Directors	04-11	CF
Novacyt's New CEO to Start May	04-11	MT
Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024	04-11	CI
Novacyt S.A. Announces CEO Changes, Effective on May 1, 2024	04-11	CI
Novacyt S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
FTSE 100 Closes Up 0.9%, Lifted by BP	02-06	DJ
Novacyt says talks to sell Taiwan laboratory are terminated	02-06	AN
Novacyt: Taiwanese laboratory retained	02-06	CF
Novacyt's Discussions for Taiwanese Unit Sale Fall Through	02-06	MT
Treatt revenue falls; Secure Trust profit picks up	01-25	AN
Novacyt appoints new CFO	01-02	CF

Chart Novacyt

Duration

Period

More charts

Company Profile

Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.

Sector

Biotechnology & Medical Research

Calendar

08:00am - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
NOVACYT	-26.37%	43.39M
MIMEDX GROUP, INC.	-14.94%	1.1B
NIBEC CO., LTD.	-10.85%	148M
KIM FOREST ENTERPRISE CO., LTD.	+3.01%	58.13M
COLLPLANT BIOTECHNOLOGIES LTD.	-21.13%	56.59M

Bio Medical Devices